ClinicalTrials.gg
CompletedNCT00985725Updated Jun 8, 2021Results posted

SPD489 in Adults With Persistent Executive Function Impairments (EFI) and Partial or Full Remission of Recurrent Major Depressive Disorder

A Phase 2 interventional study of SPD489 (Lisdexamfetamine dimesylate) and Matching placebo in Major Depressive Disorder, sponsored by Shire. Completed at 33 sites in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2021-06-08.

Sponsored by Shire (part of Takeda) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
143
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies in Depressive Disorder, Major by Takeda — 1 open to participants now, 1 under way, 1 of them phase 3. Depressive Disorder, Major · Takeda.

Enrollment
21st of 24
143 · median 580
Started
2009
with 1 other
Phase 2
4 of 26
none open now
Registered
6th of 26
by date

Among the 26 studies in Depressive Disorder, Major by Takeda, this one is the 21st largest by enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2009, is one of 4 in phase 2, and was the 6th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 26 studies in Depressive Disorder, Major by Takeda is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Depressive Disorder, Major by Takeda, or all of them as a file.
02

Study summary

To evaluate the efficacy of SPD489 for the treatment of executive function impairments (EFI) when used as an adjunct to stable, standard therapy in the setting of partial or full remission from recurrent Major Depressive Disorder (MDD) as measured by the Global Executive Composite (GEC) T-score of the Behavioral Rating Inventory of Executive Functioning - Adult Version (BRIEF-A).

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • Major Depressive Disorder
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18-55 with a primary diagnosis of nonpsychotic uni-polar depression

Exclusion criteria

Exclusion Criteria:

  • Current co-morbid psychiatric disorder
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
143 participants (actual)

Study arms

  • Experimental
    Active

    SPD489

    Drug: SPD489 (Lisdexamfetamine dimesylate)

  • Placebo comparator
    Placebo

    Placebo

    Drug: Matching placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Behavior Rating Inventory of Executive Function - Adult Version Global Executive Composite T-score (BRIEF-A GEC T) at Week 9, Last Observation Carried Forward (LOCF)

    BRIEF-A Global Executive Composite assesses behavioral aspects of executive function. Items are rated 1 (never), 2 (sometimes), and 3 (often). There is no range for a total score. Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.

    Time frame: Baseline and week 9

Secondary outcomes

  1. Change From Baseline in Montgomery-Ǻsberg Depression Rating Scale (MADRS) Total Score at Week 9 - (LOCF)

    MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression.

    Time frame: Baseline and week 9

  2. Change From Baseline in BRIEF-A T-scores at Week 9, LOCF

    BRIEF-A is a validated 75-item questionnaire. Items are rated 1 (never), 2 (sometimes), and 3 (often). There is no range for a total score. Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.

    Time frame: Baseline and week 9

  3. Change From Baseline in Central Nervous System Vital Signs Computerized Cognitive Testing Battery Neurocognitive Domain and Index Scores at up to 9 Weeks/Endpoint

    This measures the speed and accuracy of basic mental functions. Scores are normalized from raw scores and present an age matched score relative to other people in a normative sample. Scores are normalized with a mean of 100 and standard deviation of 15. Scores \< 70 indicate likely deficit and impairment, and scores \> 110 indicate high function and capacity. Higher scores are better.

    Time frame: Baseline and up to 9 weeks/Endpoint

  4. Percent of Participants With Clinical Global Impression - Severity of Illness (CGI-S) at Baseline

    CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)

    Time frame: Baseline

  5. Percent of Participants With CGI-S at up to 9 Weeks/Endpoint

    CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)

    Time frame: Up to 9 weeks/Endpoint

  6. Percentage of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) at Week 9, LOCF

    Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.

    Time frame: Week 9

  7. Change From Baseline in Endicott Work Productivity Scale (EWPS) Total Score at up to 9 Weeks/Endpoint

    The EWPS quantifies work performance, productivity attitudes and behaviors assessing 25 items on a scale ranging from 0 (high performance) to 4 (lowest performance). Scores range from 0 to 100 with 100 representing lowest productivity.

    Time frame: Baseline and up to 9 weeks/Endpoint

  8. Change From Baseline in Changes in Sexual Functioning Questionnaire (CSFQ-14) Total Scores for Males at Week 9, LOCF

    This is a 14 item self-report tool that evaluates sexual functioning. Each item is scored on a 5-point Likert scale ranging from 1 (never) to 5 (always) with total scores ranging from 14 to 70. Higher scores reflect better sexual functioning.

    Time frame: Baseline and week 9

  9. Change From Baseline in CSFQ-14 Total Scores for Females at Week 9, LOCF

    This is a 14 item self-report tool that evaluates sexual functioning. Each item is scored on a 5-point Likert scale ranging from 1 (never) to 5 (always) with total scores ranging from 14 to 70. Higher scores reflect better sexual functioning.

    Time frame: Baseline and week 9

  10. Change From Baseline in Short Form-12 Health Survey (SF-12) Scale Total Scores at Week 9

    The SF-12 is a 12-item self-report questionnaire that is a subset of the SF-36 Health Survey. The survey captures physical and mental health. Each of the 12 items is scored using various scales with a total score ranging from 0 (lowest level of health) to 100 (highest level of health).

    Time frame: Baseline and week 9

  11. Change From Baseline in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) Total Scores at up to 9 Weeks/Endpoint

    The Q-LES-Q is a 93-item self-report questionnaire on quality of life and health. Each item is rated on a 5-point scale from 1 (very poor) to 5 (very good) with a total score ranging from 93 to 465. Higher scores indicate greater satisfaction.

    Time frame: Baseline and up to 9 weeks/Endpoint

  12. Change From Baseline in Amphetamine Cessation Symptom Assessment (ACSA) Total Score at Week 11

    ACSA scale has 16 symptom items rated on a scale from 0 (not at all) to 4 (extremely) with a possible total score range of 0 to 64. Higher scores indicate greater withdrawal symptom severity.

    Time frame: Baseline and week 11

  13. Change From Baseline in the Generalized Anxiety Disorder 7-Item (GAD-7) Total Score at Week 9, LOCF

    The GAD-7 is a 7-item self-report questionnaire for assessing anxiety severity. Each item is scored using a scale that ranges from 0 (not at all) to 3 (nearly every day) with total scores ranging from 0 to 21. Lower scores indicate a reduction in anxiety.

    Time frame: Baseline and week 9

  14. Change From Baseline in Sheehan Suicidality Tracking Scale (STS) Total Score at Week 9

    The STS is an 8-question clinician-rated assessment of suicidal ideation, suicidal behavior, and accidents. The items are scored on a 5-point Likert scale from 0 (not at all) to 4 (extremely) and summed to produce a total score ranging from 0 to 32. Lower scores indicate reduced suicidal tendencies.

    Time frame: Baseline and week 9

07

Results

Posted Apr 6, 2012

Participant flow

Participant flow — Overall Study
MilestoneLisdexamfetamine Dimesylate (LDX)Placebo
Started7172
Completed6059
Not completed1113
Withdrew: Adverse event41
Withdrew: Protocol violation13
Withdrew: Withdrawal by subject44
Withdrew: Lost to follow-up11
Withdrew: Lack of efficacy01
Withdrew: Non-compliance12
Withdrew: Out-of-window visits01

Outcome measures

PrimaryChange From Baseline in Behavior Rating Inventory of Executive Function - Adult Version Global Executive Composite T-score (BRIEF-A GEC T) at Week 9, Last Observation Carried Forward (LOCF)

BRIEF-A Global Executive Composite assesses behavioral aspects of executive function. Items are rated 1 (never), 2 (sometimes), and 3 (often). There is no range for a total score. Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.

Time frame:
Baseline and week 9
Reported as:
Least squares mean · T-scores
Change From Baseline in Behavior Rating Inventory of Executive Function - Adult Version Global Executive Composite T-score (BRIEF-A GEC T) at Week 9, Last Observation Carried Forward (LOCF)
T-scoresLisdexamfetamine Dimesylate (LDX)Placebo
Change From Baseline in Behavior Rating Inventory of Executive Function - Adult Version Global Executive Composite T-score (BRIEF-A GEC T) at Week 9, Last Observation Carried Forward (LOCF)-21.2 ± 1.67-13.2 ± 1.66
Statistical analysis
  • Lisdexamfetamine Dimesylate (LDX) vs Placebo · ANCOVA · p = 0.0009 · Mean difference (final values): -8.0 · 95% CI -12.7 to -3.3
SecondaryChange From Baseline in Montgomery-Ǻsberg Depression Rating Scale (MADRS) Total Score at Week 9 - (LOCF)

MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression.

Time frame:
Baseline and week 9
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Montgomery-Ǻsberg Depression Rating Scale (MADRS) Total Score at Week 9 - (LOCF)
Scores on a scaleLisdexamfetamine Dimesylate (LDX)Placebo
Change From Baseline in Montgomery-Ǻsberg Depression Rating Scale (MADRS) Total Score at Week 9 - (LOCF)-5.0 ± 0.66-3.1 ± 0.66
Statistical analysis
  • Lisdexamfetamine Dimesylate (LDX) vs Placebo · ANCOVA · p = 0.0465 · Mean difference (final values): -1.9 · 95% CI -3.7 to 0.0
SecondaryChange From Baseline in BRIEF-A T-scores at Week 9, LOCF

BRIEF-A is a validated 75-item questionnaire. Items are rated 1 (never), 2 (sometimes), and 3 (often). There is no range for a total score. Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.

Time frame:
Baseline and week 9
Reported as:
Least squares mean · T-scores
Change From Baseline in BRIEF-A T-scores at Week 9, LOCF
T-scoresLisdexamfetamine Dimesylate (LDX)Placebo
Behavioral recognition index-17.4 ± 1.51-12.3 ± 1.50
Inhibit subscale-13.5 ± 1.26-9.3 ± 1.25
Shift subscale-16.2 ± 1.51-10.6 ± 1.50
Emotional control subscale-13.8 ± 1.48-10.1 ± 1.47
Self-monitor subscale-13.8 ± 1.36-10.7 ± 1.35
Metacognition index-21.1 ± 1.67-12.2 ± 1.66
Initiate subscale-19.4 ± 1.57-10.8 ± 1.56
Working memory subscale-20.1 ± 1.65-11.0 ± 1.64
Plan/Organize subscale-18.7 ± 1.58-11.3 ± 1.57
Task monitor subscale-16.8 ± 1.63-11.9 ± 1.62
Organization of materials subscale-15.2 ± 1.49-8.2 ± 1.48
Statistical analysis
  • Lisdexamfetamine Dimesylate (LDX) vs Placebo · ANCOVA · p = 0.0181 · Mean difference (final values): -5.1 · 95% CI -9.4 to -0.9
  • Lisdexamfetamine Dimesylate (LDX) vs Placebo · ANCOVA · p = 0.0204 · Mean difference (final values): -4.2 · 95% CI -7.7 to -0.7
  • Lisdexamfetamine Dimesylate (LDX) vs Placebo · ANCOVA · p = 0.0090 · Mean difference (final values): -5.6 · 95% CI -9.8 to -1.4
  • Lisdexamfetamine Dimesylate (LDX) vs Placebo · ANCOVA · p = 0.0793 · Mean difference (final values): -3.7 · 95% CI -7.9 to 0.4
  • Lisdexamfetamine Dimesylate (LDX) vs Placebo · ANCOVA · p = 0.1014 · Mean difference (final values): -3.2 · 95% CI -7.0 to 0.6
  • Lisdexamfetamine Dimesylate (LDX) vs Placebo · ANCOVA · p = 0.0002 · Mean difference (final values): -9.0 · 95% CI -13.7 to -4.3
  • Lisdexamfetamine Dimesylate (LDX) vs Placebo · ANCOVA · p = 0.0002 · Mean difference (final values): -8.6 · 95% CI -12.9 to -4.2
  • Lisdexamfetamine Dimesylate (LDX) vs Placebo · ANCOVA · p = 0.0001 · Mean difference (final values): -9.1 · 95% CI -13.7 to -4.5
  • Lisdexamfetamine Dimesylate (LDX) vs Placebo · ANCOVA · p = 0.0010 · Mean difference (final values): -7.5 · 95% CI -11.9 to -3.1
  • Lisdexamfetamine Dimesylate (LDX) vs Placebo · ANCOVA · p = 0.0357 · Mean difference (final values): -4.9 · 95% CI -9.4 to -0.3
  • Lisdexamfetamine Dimesylate (LDX) vs Placebo · ANCOVA · p = 0.0012 · Mean difference (final values): -7.0 · 95% CI -11.1 to -2.8
SecondaryChange From Baseline in Central Nervous System Vital Signs Computerized Cognitive Testing Battery Neurocognitive Domain and Index Scores at up to 9 Weeks/Endpoint

This measures the speed and accuracy of basic mental functions. Scores are normalized from raw scores and present an age matched score relative to other people in a normative sample. Scores are normalized with a mean of 100 and standard deviation of 15. Scores \< 70 indicate likely deficit and impairment, and scores \> 110 indicate high function and capacity. Higher scores are better.

Time frame:
Baseline and up to 9 weeks/Endpoint
Reported as:
Mean · Response scores
Change From Baseline in Central Nervous System Vital Signs Computerized Cognitive Testing Battery Neurocognitive Domain and Index Scores at up to 9 Weeks/Endpoint
Response scoresLisdexamfetamine Dimesylate (LDX)Placebo
Complex information speed processing index8.7 ± 10.133.7 ± 9.02
Executive function index11.0 ± 14.806.0 ± 14.43
Neurocognitive index11.5 ± 17.142.5 ± 13.74
SecondaryPercent of Participants With Clinical Global Impression - Severity of Illness (CGI-S) at Baseline

CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)

Time frame:
Baseline
Reported as:
Number · percentage of participants
Percent of Participants With Clinical Global Impression - Severity of Illness (CGI-S) at Baseline
percentage of participantsLisdexamfetamine Dimesylate (LDX)Placebo
Normal, not at all ill0.02.8
Borderline mentally ill7.08.3
Mildly ill42.336.1
Moderately ill45.148.6
Markedly ill4.24.2
Severely ill1.40.0
Among the most extremely ill0.00.0
SecondaryPercent of Participants With CGI-S at up to 9 Weeks/Endpoint

CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)

Time frame:
Up to 9 weeks/Endpoint
Reported as:
Number · percentage of participants
Percent of Participants With CGI-S at up to 9 Weeks/Endpoint
percentage of participantsLisdexamfetamine Dimesylate (LDX)Placebo
Normal, not at all ill21.715.9
Borderline mentally ill40.623.2
Mildly ill20.324.6
Moderately ill14.534.8
Markedly ill2.91.4
Severely ill0.00.0
Among the most extremely ill0.00.0
SecondaryPercentage of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) at Week 9, LOCF

Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.

Time frame:
Week 9
Reported as:
Number · percentage of participants
Percentage of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) at Week 9, LOCF
percentage of participantsLisdexamfetamine Dimesylate (LDX)Placebo
Percentage of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) at Week 9, LOCF60.638.9
SecondaryChange From Baseline in Endicott Work Productivity Scale (EWPS) Total Score at up to 9 Weeks/Endpoint

The EWPS quantifies work performance, productivity attitudes and behaviors assessing 25 items on a scale ranging from 0 (high performance) to 4 (lowest performance). Scores range from 0 to 100 with 100 representing lowest productivity.

Time frame:
Baseline and up to 9 weeks/Endpoint
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Endicott Work Productivity Scale (EWPS) Total Score at up to 9 Weeks/Endpoint
Scores on a scaleLisdexamfetamine Dimesylate (LDX)Placebo
Change From Baseline in Endicott Work Productivity Scale (EWPS) Total Score at up to 9 Weeks/Endpoint-20.4 ± 2.24-15.9 ± 2.32
Statistical analysis
  • Lisdexamfetamine Dimesylate (LDX) vs Placebo · ANCOVA · p = 0.1731 · Mean difference (final values): -4.4 · 95% CI -10.9 to 2.0
SecondaryChange From Baseline in Changes in Sexual Functioning Questionnaire (CSFQ-14) Total Scores for Males at Week 9, LOCF

This is a 14 item self-report tool that evaluates sexual functioning. Each item is scored on a 5-point Likert scale ranging from 1 (never) to 5 (always) with total scores ranging from 14 to 70. Higher scores reflect better sexual functioning.

Time frame:
Baseline and week 9
Reported as:
Mean · Scores on a scale
Change From Baseline in Changes in Sexual Functioning Questionnaire (CSFQ-14) Total Scores for Males at Week 9, LOCF
Scores on a scaleLisdexamfetamine Dimesylate (LDX)Placebo
Change From Baseline in Changes in Sexual Functioning Questionnaire (CSFQ-14) Total Scores for Males at Week 9, LOCF2.5 ± 4.612.4 ± 5.34
SecondaryChange From Baseline in CSFQ-14 Total Scores for Females at Week 9, LOCF

This is a 14 item self-report tool that evaluates sexual functioning. Each item is scored on a 5-point Likert scale ranging from 1 (never) to 5 (always) with total scores ranging from 14 to 70. Higher scores reflect better sexual functioning.

Time frame:
Baseline and week 9
Reported as:
Mean · Scores on a scale
Change From Baseline in CSFQ-14 Total Scores for Females at Week 9, LOCF
Scores on a scaleLisdexamfetamine Dimesylate (LDX)Placebo
Change From Baseline in CSFQ-14 Total Scores for Females at Week 9, LOCF2.7 ± 8.471.6 ± 5.60
SecondaryChange From Baseline in Short Form-12 Health Survey (SF-12) Scale Total Scores at Week 9

The SF-12 is a 12-item self-report questionnaire that is a subset of the SF-36 Health Survey. The survey captures physical and mental health. Each of the 12 items is scored using various scales with a total score ranging from 0 (lowest level of health) to 100 (highest level of health).

Time frame:
Baseline and week 9
Reported as:
Mean · Scores on a scale
Change From Baseline in Short Form-12 Health Survey (SF-12) Scale Total Scores at Week 9
Scores on a scaleLisdexamfetamine Dimesylate (LDX)Placebo
Aggregate physical-0.10 ± 0.461-0.23 ± 0.473
Aggregate mental0.69 ± 0.9870.63 ± 0.807
SecondaryChange From Baseline in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) Total Scores at up to 9 Weeks/Endpoint

The Q-LES-Q is a 93-item self-report questionnaire on quality of life and health. Each item is rated on a 5-point scale from 1 (very poor) to 5 (very good) with a total score ranging from 93 to 465. Higher scores indicate greater satisfaction.

Time frame:
Baseline and up to 9 weeks/Endpoint
Reported as:
Mean · Scores on a scale
Change From Baseline in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) Total Scores at up to 9 Weeks/Endpoint
Scores on a scaleLisdexamfetamine Dimesylate (LDX)Placebo
Physical health activities17.9 ± 20.038.2 ± 16.82
Overall life satisfaction12.1 ± 25.379.1 ± 22.27
SecondaryChange From Baseline in Amphetamine Cessation Symptom Assessment (ACSA) Total Score at Week 11

ACSA scale has 16 symptom items rated on a scale from 0 (not at all) to 4 (extremely) with a possible total score range of 0 to 64. Higher scores indicate greater withdrawal symptom severity.

Time frame:
Baseline and week 11
Reported as:
Mean · Scores on a scale
Change From Baseline in Amphetamine Cessation Symptom Assessment (ACSA) Total Score at Week 11
Scores on a scaleLisdexamfetamine Dimesylate (LDX)Placebo
Change From Baseline in Amphetamine Cessation Symptom Assessment (ACSA) Total Score at Week 11-9.4 ± 14.43-5.9 ± 10.86
SecondaryChange From Baseline in the Generalized Anxiety Disorder 7-Item (GAD-7) Total Score at Week 9, LOCF

The GAD-7 is a 7-item self-report questionnaire for assessing anxiety severity. Each item is scored using a scale that ranges from 0 (not at all) to 3 (nearly every day) with total scores ranging from 0 to 21. Lower scores indicate a reduction in anxiety.

Time frame:
Baseline and week 9
Reported as:
Mean · Scores on a scale
Change From Baseline in the Generalized Anxiety Disorder 7-Item (GAD-7) Total Score at Week 9, LOCF
Scores on a scaleLisdexamfetamine Dimesylate (LDX)Placebo
Change From Baseline in the Generalized Anxiety Disorder 7-Item (GAD-7) Total Score at Week 9, LOCF-4.4 ± 5.81-3.8 ± 5.43
SecondaryChange From Baseline in Sheehan Suicidality Tracking Scale (STS) Total Score at Week 9

The STS is an 8-question clinician-rated assessment of suicidal ideation, suicidal behavior, and accidents. The items are scored on a 5-point Likert scale from 0 (not at all) to 4 (extremely) and summed to produce a total score ranging from 0 to 32. Lower scores indicate reduced suicidal tendencies.

Time frame:
Baseline and week 9
Reported as:
Mean · Scores on a scale
Change From Baseline in Sheehan Suicidality Tracking Scale (STS) Total Score at Week 9
Scores on a scaleLisdexamfetamine Dimesylate (LDX)Placebo
Change From Baseline in Sheehan Suicidality Tracking Scale (STS) Total Score at Week 9-0.1 ± 0.400.0 ± 0.13

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lisdexamfetamine Dimesylate (LDX)—2/71 (2.8%)56/71 (78.9%)
Placebo—4/72 (5.6%)53/72 (73.6%)
Most frequent serious events
Most frequent serious events
EventLisdexamfetamine Dimesylate (LDX)Placebo
Loss of consciousnessNervous system disorders1/710/72
Suicidal ideationPsychiatric disorders1/710/72
GastroenteritisInfections and infestations0/711/72
RhabdomyolysisMusculoskeletal and connective tissue disorders0/711/72
SalmonellosisInfections and infestations0/711/72
Pelvic inflammatory diseaseInfections and infestations0/711/72
Most frequent other events
Showing 10 of 36
Most frequent other events
EventLisdexamfetamine Dimesylate (LDX)Placebo
Decreased appetiteInvestigations16/713/72
HeadacheNervous system disorders16/7111/72
Dry mouthGastrointestinal disorders11/716/72
InsomniaPsychiatric disorders10/712/72
IrritabilityGeneral disorders9/715/72
Urinary tract infectionInfections and infestations7/713/72
Upper respiratory tract infectionInfections and infestations6/714/72
AnxietyPsychiatric disorders6/714/72
NauseaGastrointestinal disorders5/714/72
FatigueGeneral disorders4/714/72

Baseline characteristics

Age, Continuous
Age, Continuous(years)Lisdexamfetamine Dimesylate (LDX)PlaceboTotal
Mean41.9 ± 9.7939.5 ± 10.5940.7 ± 10.23
Age, Customized
Age, Customized(Participants)Lisdexamfetamine Dimesylate (LDX)PlaceboTotal
18 to 39 years283462
40 to 55 years433881
Sex: Female, Male
Sex: Female, Male(Participants)Lisdexamfetamine Dimesylate (LDX)PlaceboTotal
Female514899
Male202444
Region of Enrollment
Region of Enrollment(Participants)Lisdexamfetamine Dimesylate (LDX)PlaceboTotal
United States7172143
08

Study locations

33 sites
  • Sun Valley Research Center
    Imperial, California 92251, United States
  • Pharmacology Research Center
    Los Alamitos, California 90720, United States
  • Excell Research
    Oceanside, California 92056, United States
  • Neuropsychiatric Resesarch Center of Orange County
    Santa Ana, California 92701, United States
  • Connecticut Clincal Research
    Cromwell, Connecticut 06416, United States
  • Clinical Neuroscience Solutions, Inc.
    Jacksonville, Florida 32216, United States
  • Amit Vijapura, MD
    Jacksonville, Florida 32256, United States
  • Scientific Clinical Research, Inc.
    North Miami, Florida 33161, United States
  • Clinical Neuroscience Solutions, Inc.
    Orlando, Florida 32806, United States
  • Atlanta Institute of Medicine & Research
    Atlanta, Georgia 30328, United States
  • Carman Research
    Smyrna, Georgia 30080, United States
  • Joliet Center for Clinical Research
    Joliet, Illinois 60435, United States
  • Capstone Clinical Research
    Libertyville, Illinois 60048, United States
  • Psychiatric Associates
    Overland Park, Kansas 66211, United States
  • AccelRx Research
    Fall River, Massachusetts 02721, United States
  • St. Charles Psychiatric Associates
    Saint Charles, Missouri 63301, United States
  • PsychCare Consultants Research
    Saint Louis, Missouri 63128, United States
  • Premier Psychiatric Research Institute, LLC
    Lincoln, Nebraska 68510, United States
  • Richmond Behavioral Associates
    Staten Island, New York 10312, United States
  • North Carolina Neuropsychiatry, PA
    Chapel Hill, North Carolina 27514, United States
  • Duke University Medical Center
    Durham, North Carolina 27705, United States
  • Richard H. Weisler, MD, PA & Associates
    Raleigh, North Carolina 27609, United States
  • Patient Priority Clinical Sites, LLC
    Cincinnati, Ohio 45242, United States
  • Lehigh Center for Clinical Research
    Allentown, Pennsylvania 18104, United States
  • Paramount Clinical Research
    Bridgeville, Pennsylvania 15017, United States
  • Suburban Research Associates
    Media, Pennsylvania 19063, United States
  • FutureSearch Trials of Dallas, LP
    Dallas, Texas 75231, United States
  • Bayou City Resesarch, LTD
    Houston, Texas 77007, United States
  • Red Oak Psychiatry Associates, PA
    Houston, Texas 77090, United States
  • University Hills Clinical Research
    Irving, Texas 75062, United States
  • R/D Clinical Research, Inc.
    Lake Jackson, Texas 77566, United States
  • Wharton Research Center
    Wharton, Texas 77488, United States
  • Northwest Clinical Research Center
    Bellevue, Washington 98007, United States
09

References and documents

Publications

  • Madhoo M, Keefe RS, Roth RM, Sambunaris A, Wu J, Trivedi MH, Anderson CS, Lasser R. Lisdexamfetamine dimesylate augmentation in adults with persistent executive dysfunction after partial or full remission of major depressive disorder. Neuropsychopharmacology. 2014 May;39(6):1388-98. doi: 10.1038/npp.2013.334. Epub 2013 Dec 6. PubMed 24309905 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2009 to primary completion in Apr 2011, 17 months.

Results were first posted in Apr 2012, 11 months after primary completion.

Of 96 industry-sponsored phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 23. This study's 17 months is close to that.

Counting every sponsor, half of 195 studies reached it within 22 months; a quarter within 14 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2009
First posted
Sep 28, 2009
StartActual
Oct 29, 2009
Primary completionActual
Apr 18, 2011
CompletionActual
Apr 18, 2011
Results first posted
Apr 6, 2012
Last update
Jun 8, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00985725
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Sep 28, 2009
Start date
Oct 29, 2009
Primary completion
Apr 18, 2011
Completion
Apr 18, 2011
Results posted
Apr 6, 2012
Last update
Jun 8, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lisdexamfetamine

Start the discussion